All In Biotech

Drug Trial Radar · NCT05379829

A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation

Pharmacokinetics, Pharmacodynamics and Safety of Ziltivekimab Versus Placebo in Chinese Participants With Chronic Kidney Disease and Systemic Inflammation

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

May 30, 2022

Primary completion

Jun 12, 2024

Study completion Sep 2, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted to see how the ziltivekimab works in the body of Chinese people with chronic kidney disease and systemic inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body. Participants' chance of getting ziltivekimab or placebo is the same. Participants will get their study medicine in a pre-filled syringe. The study doctor or staff will do 3 injections of study medicine during clinical visits. The study is expected to last for about 6 months. Participants will have blood and urine samples taken at all of the clinic visits. Participants will have their heart examined using electrodes (electrocardiogram). Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Conditions

  • Chronic Kidney Disease and Systemic Inflammation

Interventions

  • ZiltivekimabDrug

    Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).

  • PlaceboDrug

    Participants will be administered 3 doses s.c. Q4W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the ziltivekimab plasma concentration-time curve in a 4-week dosing interval, multiple doses [MD] (AUCτ,MD)Time frame: During 3rd dosing interval (week 8 to week 12)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Chinses People's Liberation Army General Hospital-Nephrology

    Beijing, Beijing Municipality, China

  • Zhongda Hospital Southeast University-Nephrology

    Nanjing, Jiangsu, China

  • Zhongda Hospital Southeast University-Neurology

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University-Endocrinology

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital Of Soochow University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.